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Abstract.  The carbohydrate determinants recognized 
by the HNK-1 antibody are potential cell-cell recogni- 
tion ligands in the peripheral  nervous system (PNS). 
The HNK-1  reactive sulfoglucuronylneolacto (SGNL) 
glycolipids specifically support Schwann cell adhesion, 
suggesting the presence of a cell surface receptor 
specific for SGNL-oligosaccharides. We directly 
probed PNS membranes for receptors complementary 
to SGNL determinants using a  synthetic radioligand 
consisting of radioiodinated  serum albumin derivatized 
with multiple SGNL-oligosaccharides. A  high-affinity, 
saturable,  calcium-dependent binding site for this 
ligand was found in PNS myelin membranes.  Binding 
activity was carbohydrate-specific (most potently in- 
hibited by SGNL-lipids compared to other glycolipids) 
and PNS-specific (absent from comparable central ner- 
vous system membranes).  The SGNL-specific binding 
activity on PNS membranes reported here may be in- 
volved in peripheral  myelination or myelin stabili- 
zation. 
ECENTLY, unusual  carbohydrate determinants  recog- 
nized  by the HNK-1 mAb and the monoclonal L2 
antibodies have been proposed to function  in neural 
recognition, perhaps as adhesive  determinants  (9, 26, 47). 
HNK-1 reactive species include a unique class of anionic 
glycosphingolipids, the sulfoglucuronylneolacto-lipids (SGNL- 
lipids) ~, in addition  to undefined,  but presumably related, 
carbohydrate determinants  on minor glycoforms of adhesive 
glycoproteins  including  NCAM,  MAG,  Po,  L1,  and 
J1/cytotactin (50). Consistent with a role in cell recognition, 
HNK-I and L2 mAbs attenuate cell adhesion in several neu- 
ral cell model systems in vitro (9, 26, 47). The observation 
that  SGNL-lipids  and  SGNL-oligosaccharides  perturb 
cell-cell  and  cell-substratum  adhesion  in  vitro  provides 
more direct evidence for a  role of these HNK-1 reactive 
oligosaccharides as authentic  adhesive  ligands  (29). 
Further  evidence for an adhesive  role for SGNL-deter- 
minants comes from clinical studies. SGNL-lipids were first 
identified  as antigens  of monoclonal IgM's  produced by a 
majority of patients  with peripheral demyelinating  neurop- 
athy associated with IgM paraproteinemia (excess produc- 
tion of monoclonal IgM).  These IgM paraproteins  exhibit 
carbohydrate structural  specificities  similar  to the HNK-1 
and L2 antibodies (45, 62). The two major structurally char- 
acterized SGNL-lipids are closely related and consist of a 
nonreducing  terminal  glucuronic  acid  3-sulfate  attached 
(/31-3) to the terminal galactose of neolactotetraosylceramide 
1. Abbreviations  used in this paper:  CNS, central nervous system; CMF- 
PBS, divalent cation-free phosphate buffered saline; PNS, peripheral ner- 
vous system; SGNL, sulfoglucuronylneolacto. 
or neolactohexaosylceramide  (1, 6). SGNL-lipids are found 
in the adult peripheral nervous system (PNS) of  many species 
(7, 23), but are not detected in adult cerebral cortex, although 
they are expressed in embryonic cortex and in adult cerebel- 
lum (8, 43). In the PNS, subcellular fractionation  has local- 
ized  SGNL-lipids  to  the  axolemma-enriched  fraction,  as 
well as myelin and other Schwann cell membranes (27). 
We have focused on the possible role of the SGNL-lipids 
as adhesive ligands recognized by Schwann cell surface recep- 
tors. The initial impetus  for pursuing  this hypothesis  arose 
from the following observations.  (a) The pathology and mor- 
phological changes in the subclass of  patients with peripheral 
demyelinating neuropathy  associated with a SGNL-lipid re- 
active  IgM paraprotein  is  consistent with a  disruption  of 
Schwann cell surface interactions necessary for myelin main- 
tenance or myelination (44, 53). (b) SGNL-lipids are present 
in the membranes of axons and Schwarm cells (27), and are 
therefore in the proper location to mediate axon-Schwann cell 
or myelin lameUae-lamellae interactions.  (c) SGNL-lipids 
and SGNL-oligosaccharides are capable of inhibiting neural 
cell-cell and cell-substratum interactions  in vitro (29).  (d) 
There is a growing body of evidence that glycosphingolipids 
may function as determinants  in cell-cell interactions  in- 
volved in leukocyte and platelet adhesion  to vascular endo- 
thelium and in neural cell recognition  (3, 17, 51). In particu- 
lar, the demonstration  of a carbohydrate-specific  ganglioside 
binding  protein  that  is present  in central  nervous  system 
(CNS) but not PNS myelin and which may be involved in oli- 
godendrocyte-axon  interactions (58, 59) raised the possibility 
that another class of anionic glycosphingolipids,  the SGNL- 
lipids,  may be playing a similar role in PNS myelin.  More- 
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hesion  directly  and  selectively to  SGNL-lipids,  using  a 
technique which detects adhesion of intact cells directly to 
chromatographically resolved lipids (57).  When peripheral 
nerve lipids were resolved by TLC and overlaid with radio- 
labeled Schwann cells, the SGNL-lipids supported cell adhe- 
sion with greater potency than any other PNS lipids (38). The 
adhesion was cell type specific in that neither hepatocytes, 
fibroblasts, nor retina cells adhered to the SGNL-lipids (39). 
These data suggest the presence of a Schwann cell surface 
receptor specific for the SGNL-oligosaccharide. 
To probe directly for the presence of a SGNL-oligosac- 
charide receptor in the PNS, we constructed a multivalent 
radioligand consisting of SGNL-oligosaccharides covalently 
attached to a radioiodinated carrier protein, BSA. Through 
the use of this ligand, we now report the properties of a com- 
plementary SGNL-specific binding site on PNS myelin. 
Materials and Methods 
SG  NL-lipid Purification 
SGNL-lipids were purified from dog sciatic nerve endoneurium (Pei-Freeze 
Biologicals, Rogers, AR), from bovine cauda equina (obtained at time of 
slaughter),  or from human cauda equina (obtained at autopsy or kindly 
provided by the National Neurological Research Specimen Bank, Los An- 
geles,  CA)  using  modifications  of published  procedures  (1,  6).  Tissue 
('~100 g wet weight, stored at -70°C before use) was thawed, homogenized 
in a Polytron high-speed motor-driven homogenizer (dog and bovine tissue) 
or a Waring blender (human tissue), and extracted sequentially with 15 and 
7.5 vol (relative to the original tissue wet weight) chloroform/methanol/wa- 
ter (4:8:3) ([56]; all solvent ratios are vol/vol). Precipitated protein was re- 
moved by centrifugation, and the supernatant evaporated to dryness. The 
resulting residue was extracted by incubation in 4 vol of chloroform/metha- 
nol (1:1) for ,'016 h at 4°C. The remaining solids were recovered by centrifu- 
gation and dissolved in 2.5 vol of chloroform/methanol/water (4:8:3). After 
removal of the remaining precipitate by centrifugation, water was added to 
a final ratio of chloroform/methanol/water of 4:8:5.6 (56). The resulting up- 
per aqueous phase was readjusted to chloroform/methanol/water (4:8:3) 
and applied to a  column  (0.25  vol relative to original tissue weight) of 
DEAE-Sepharose Fast Flow (acetate form, Pharmacia LKB Biotechnology 
Inc.,  Piscataway,  NJ) equilibrated in the same solvent.  The column was 
eluted with 2 column vol of the starting solvent, 8 column vol of methanol, 
4 column vol of 0.04 M ammonium acetate in methanol, and 4 column vol 
of 0.1 M ammonium acetate in methanol to elute pbospholipids, sulfatides, 
and  gangliosides  (18,  35).  The  SGNL-lipids  were  then eluted  with  10 
column vol of 0.2 M ammonium acetate in methanol. This fraction was con- 
centrated on a vacuum rotary evaporator (Rotovap, Biichi), diluted with wa- 
ter, and dried on a vacuum centrifugal evaporator (Speedvac, Savant) to re- 
move  volatile  salts.  The  residue  was  dissolved  in  8  ml  chloroform: 
methanol/water (70:30:4), and applied to a  1-ml column of Iatrobeads si- 
licic acid (Iatron Laboratories, Tokyo, Japan). The column was washed with 
6  ml chloroform/methanol/water (70:30:4), and SGNL-lipids were eluted 
in 2 ml chloroform/methanol/water (60:35:8) followed by 4 ml of 10:10:3. 
The latter two fractions were pooled, evaporated, and dissolved in chloro- 
form/methanol/water (2:43:55), and applied to two prewashed C18 Sep-Pak 
cartridges (Waters) in tandem (60). The cartridges were washed with 16 ml 
water, 8 ml methanol/water (2:1), and then SGNL-lipids were eluted with 
16 ml methanol/water (4:1) and 8 ml methanol. The purified SGNL-lipids 
were pooled,  solvents evaporated,  and the residue dissolved  in chloro- 
form/methanol/water (4:8:3) for storage. 
The purification of the SGNL-lipids was monitored by TLC on silica gel 
HPTLC  plates  (E.  Merck,  Darmstadt,  FRG)  using  chloroforrrdmetha- 
nul/0.25 % KCI (60:35:8)  as developing solvent and a variety of lipid stains 
to detect contaminating glycolipids and pbospholipids including resorcinol 
(specific for gangliosides [12,  55]), N-l-napthylethylenediamine dibydro- 
chloride (specific for sugars [2]), Azure A (specific for sulfated compounds 
[22]), and cupric sulfate/pbosphoric acid char (nonspecific lipid stain [61]). 
In the purified SGNL-lipid fraction (from all three species), two major com- 
ponents were detected  with N-l-napthyl-ethylenediamine,  Azure  A,  and 
cupric sulfate/phosphoric acid:  the most abundant species  (60-90%  de- 
pending on the  species,  Rf  =  0.20-0.24),  and a  less abundant species 
(10-35%,  Rf =  0.09-0.14).  In addition, a third species of low abundance 
(°°5%,  Rf  =  0.05)  was detected with these three stains in the purified 
SGNL-lipid fraction derived from bovine canda equina. No resoreinol posi- 
tive material was detected in these fractions. The three species were also 
detected  with  HNK-1  antibody  and  the  two  faster  migrating  species 
comigrated with authentic SGNI-4- and SGNI-~-lipids (kindly provided by 
Dr. Robert Yu, Virginia Commonwealth University, Richmond, VA). The 
HNK-1  immuno-overlay procedure  was  modified from the procedure  of 
Magnani (35) as follows. After resolution of the lipids by HPTLC, the TLC 
plates were dried at 50°C for 1 h, and then treated for 30 s sequentially with 
hexane and with 0.01%  poly(isobutylmethacrylate) (Aldrich Chem.  Co., 
Milwaukee, WI) in hexane, after which they were dried under a stream of 
air. After the plates were prewet by spraying with divalent cation-free phos- 
phate buffered saline (CMF-PBS) (16), they were incubated for ,,o16 h at 
4°C with HNK-1  antibody (Leu-7, Becton Dickinson, Mountain View, CA) 
at a dilution of 1 #g/ml in CMF-PBS containing 0.2% BSA. The TLC plate 
was washed by transfer into CMF-PBS and bound antibody localized by in- 
cubation of the  plate  with biotinylated goat anti-mouse  IgM  and with 
avidin/biotinylated horseradish  peroxidase  complex  (Vector  Labs,  Inc., 
Burlingame, CA) diluted in CMF-PBS,  followed by peroxidase detection 
using diaminobenzidine as substrate according to the manufacturer's in- 
structions for processing nitrocellulose blots. 
The concentration of SGNL-lipids was determined by quantitative TLC 
in the above solvent system and 2% Azure A in 1 mM sulfuric acid to stain 
sulfated compounds (22).  Sulfatides were used as quantitative standards. 
Alternatively, the concentration of SGNL-lipids was determined by saccha- 
ride compositional analysis using a  Dionex HPLC carbohydrate analysis 
system (see below). The two methods yielded essentially identical results. 
In addition,  SGNL-lipids were characterized by fast atom bombardment 
MS (see below). 
Synthesis of 125I-SGNL-BSA 
SGNL-oligosaccharide was released from the parent lipid using ceramide 
glycanase (V-Labs, Covington, LA) under conditions described previously 
(63). The optimal procedure is as follows. SGNL-lipid (2.6 #mol) isolated 
from  dog  sciatic  nerve  endoneurium  was  treated  with  17  U  ceramide 
glycanase for 24 h at 37°C in 6.5 m150 mM sodium acetate buffer, pH 5.0, 
containing 0.75 mg/ml sodium cholate. The reaction was stopped by the ad- 
dition of 19.5 ml of acetonitrile/water (1:2) and the solution passed over two 
C18 reverse phase cartridges in tandem to remove detergent and ceramide (6). 
The purified SGNL-oligosaccharide was conjugated to BSA by reductive 
amination using pyridine borane as reducing reagent (4). SGNL-oligosac- 
charide (,v2 #tool) was added in "~50-fold molar excess to 2.7 mg BSA (es- 
sentiaUy fatty acid- and globulin-free, Sigma Chem. Co., St. Louis, MO) 
in 320 #1 of 0.1 M sodium phosphate buffer, pH 7.0. Methanol and pyridine 
borane (40 ~1 each) were added and the reaction was allowed to proceed 
for 5.5 d at 50°C under nitrogen. Analysis of the reaction mixture by silica 
gel HPTLC (E. Merck) using n-bntanol/acetic acid/water (2:1:1) as the de- 
veloping solvent and 13 mM N-(bnapththyl)ethylenediamine dibydrochio- 
ride in 3 % sulfuric acid in methanol to visualize sugars (2) revealed the dis- 
appearance of the two oligosaccharide bands (Rf's =  0.11 and 0.05), and a 
concomitant increase in saccharide-positive material at the origin, as ex- 
pected for saccharides conjugated to protein. The reaction mixture was ex- 
tracted with ethyl acetate to remove pyridine borane and SGNL-BSA was 
purified by gel permeation chromatography on Sephadex G-25 and anion 
exchange HPLC on a Beckman DEAE (5PW) column, as described (58). 
Purified SGNL-BSA was radioiodinated using Na125I (Amersham Corp., 
Arlington Heights, IL) and Iodobends (Pierce Chem. Co. Rockford, IL) as 
previously described (58) to initial specific activities of 200-600 Ci/mmol. 
125I-SGNL-BSA Characterization 
t25I-SGNL-BSA  was  subjected  to  gradient  SDS-polyacrylamide  elec- 
trophoresis (31) as follows. Aliquots of 1251-SGNL-BSA ('~100 fmoi) were 
boiled in sample buffer containing SDS and/3-mereaptoethanoi and loaded 
onto a  10-20%  gradient polyacrylamide mini-gel (Integrated Separation 
Sys., Natick, MA). Electrophoresis was conducted at 40 milliamps constant 
current on a Hoeffer Mighty Small H apparatus. The gel was blotted onto 
nitrocellulose in using a BioRad "Transblot" electrophoretic transfer appara- 
tus. After transfer in 25 mM Tris base 192 mM glycine 20% methanol for 
3 h at 70 V, the blot was dried and exposed to X-ray film to obtain an au- 
toradiographic image, and then processed for HNK-1  reactive oligosaccha- 
ride immunolocalization. The blot was preincubated with 3% BSA in 10 
mM Tris buffer, pH 7.4, containing 15 mM NaC1, and then incubated with 
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CMF-PBS containing 0.2%  BSA. The blot was washed by transfer into 
CMF-PBS and bound antibody localized by incubation of the blot with bi- 
otinylated goat anti-mouse IgM and with avidin/biotinylated horseradish 
peroxidase complex (Vector Labs) diluted in CMF-PBS, followed  by peroxi- 
dase  detection  using  diaminobenzidine as  substrate  according  to  the 
manufacturer's instructions. 
Carbohydrate compositional analysis was performed by anion exchange 
chromatography with pulsed amperometric detection on a Dionex BioLC 
HPLC system. The glucuronic acid was converted to glucose (24)  before 
hydrolysis as follows. An aliquot of SGNL-BSA (924 pmol) or SGNL-lipid 
(,ol nmol) was evaporated in a test tube and the residue treated with 100 
t~l anhydrous 0.05 N HCI in methanol for 4 h at ambient temperature to pro- 
duce the desulfated glucuronyl-methyl ester. Sodium borate buffer,  pH 9 
(0.2 N, 10 #l), NaOH (0.5 N, 10/LI), and sodium borohydride in methanol 
(20 mg/ml, 100 td) were added to reduce the glucuronyl-methyl ester to glu- 
cose. After ',,16 h at ambient temperature, excess sodium borohydride was 
destroyed by the addition of 30 pl 2 N acetic acid. The resulting mixture 
was evaporated to dryness. The residue was hydrolyzed in 200 t~l 2  N 
trifluoroacetic acid for 5 h at 100°C to release monosaccharides. Samples 
were evaporated to dryness under a stream of nitrogen, dissolved in 250 #1 
of water, and 50/~1 aliquots were injected on a Dionex HPIC AS6 column. 
Procedures for elution and pulsed amperometric detection for quantitation 
of monosaccharides were as previously described (33). 
SGNL-BSA protein values were determined by densitometry of Amido 
Black stained nitrocellulose slot blots of protein aliquots, using the proce- 
dure of Sailer and Weissmann (48) modified as follows. Aliquots (100 ~1) 
containing 0.1-1.2 #g BSA standard or unknown sample were placed in 96- 
well polystyrene microplate wells. SDS (10%,  10/xl)  was added, the plate 
incubated for 5 min at ambient temperature, 67/~1 of 50% trichloroacetic 
acid was added, and the plate was incubated for an additional 5 rain. The 
contents of each well  were transferred to  nitrocellulose filters using  a 
Minifold II slot-blot apparatus (Schieicher and SchueU,  Inc., Keene, NH). 
Each sample application slot was washed with two~aliquots (200 #1) of 6% 
trichioroacetic acid, the nitrocellulose filter was removed from the mani- 
fold, stained for 3 rain in 0.1% Amido Black 10B in methanol/water/acetic 
acid (45:45:10),  washed in water for 1 rain, destained in methanol/water 
acetic acid (90:8:2) for 3 min, and washed in water for 1 min. Protein stain 
was quantitated using a Kontes Fiber Optic Scanner. 
SGNL-BSA and parent BSA were also analyzed by laser desorption mass 
spectroscopy (5),  which  was  kindly  performed by  Drs.  Robert Cotter 
and Marc Chevrier of the Middle Atlantic Mass Spectrometry Laboratory, 
an NSF Regional Instrumentation Facility,  Baltimore, MD. 
Peripheral Nerve Endoneurium 
Subcellular Fractionation 
Rat sciatic nerve myelin was prepared according to modifications of the 
methods of Oulton and Mezei (42) by Tiemeyer et al. (59). Rat sciatic nerve 
endoneurium was dissected from rat sciatic nerve (Pel-Freeze) in CMF- 
PBS,  the endoneurium was collected by  centrifugation, resuspended in 
0.29  M  sucrose,  and stored at  -70°C  until  use.  Thawed endoneurium 
('o2 g, from 125 nerves) was homogenized in 20 ml of  0.29 M sucrose using 
a Polytron tissue disruptor and the homogenate was centrifuged at 1,000 g 
for 10 rain to remove nondisrupted tissue, unbroken cells, and nuclei, yield- 
ing a crude supernatant "SI" fraction. In some experiments, a small portion 
of the S1 fraction was centrifuged (72,000 g, 45 min), and the pellet was 
resuspended in 1 ml 0.29 M  sucrose, diluted 10-fold with 10 mM EGTA 
in  1  mM  Hepes,  pH  Z5,  and  recentrifuged.  The  resulting pellet  was 
resuspended in a small volume of 0.29 M sucrose to yield the mixed mem- 
brane "P2" fraction. The remainder of Sl was diluted to 24 ml with 0.29 M 
sucrose and 12 ml were overlaid onto each of two discontinuous sucrose 
gradients consisting of 10 ml 0.8 M sucrose over 10 ml 1.2 M sucrose. The 
gradients were centrifuged at 72,000  g  for 2.5  h  in a  swinging bucket 
ultracentrifuge rotor. The material banding at each of the 0.29/0.8  M and 
0.8/1.2 M sucrose interfaces was collected with a pasteur pipette in '~6 ml 
vol, diluted to 36 ml with 10 mM EGTA in 1 mM Hepas, pH 7.5, and recen- 
trifuged at 72,000 g for 45 min. The pellets from the 0.29/0.8  M sucrose 
interfaces and from 0.8/1.2 M sucrose interfaces were resuspended in small 
volumes of 0.29 M sucrose to yield a myelin enriched fraction, SIA (from 
the material forming a compact white band at the 0.29/0.8  M sucrose inter- 
face), and a denser mixed membrane fraction, S1B (from the material form- 
ing a diffuse off-white band at the 0.8/1.2 M sucrose interface). In some ex- 
periments, a portion of the SIA fraction was further subjected to osmotic 
shock and homogenization and purified by subjecting it to a second discon- 
tinuous sucrose gradient centrifugation as follows. As aliquot (,°3 ml) of 
the SIA fraction was diluted with 10 vol of 10 mM EGTA in 1 mM Hepes, 
pH 7.5, homogenized manually (glass teflon, 5 strokes), and incubated on 
ice for 15 min. After centrifugation at 72,000 g for 45 min, the pellet was 
resuspended in 6 ml 0.29 M sucrose with trituration and brief homogeniza- 
tion, and resubjected to discontinuous sucrose gradient as described above, 
except that only the material banding at the 0.29/0.8  M  sucrose interface 
,was  collected by  centrifugation and  resuspended in a  small  volume of 
0.29 M sucrose to yield a purified myelin fraction, $2. All fractions were 
stored frozen in small aliquots before use. Protein content was determined 
using the bicinchoninic acid assay (52)  with BSA as a standard. 
Central Nervous System 1Issue 
SubceUular Fractionation 
Crude membrane fractions (P2) were prepared from whole rat brain and 
from cerebellum (cerebellar P2) by the differential centrifugation method 
of Cotman (11) as previously described (59). Fractions enriched in myelin 
(P2A) and in synaptosomes (P2B) were prepared from whole rat brain by 
the discontinuous sucrose gradient centrifugation method of  Gray and Whit- 
taker (19) as previously described (59). 
12~I-SGNL-BSA Binding to Membranes 
An aliquot of membranes containing 0.1-10 ftg protein in 25/~1 of 0.29 M 
sucrose was added to 225 #1 of binding buffer (50 mM imidazole acetate, 
pH 7.4,  0.032%  Triton X-100 (Surfact-Amps X-100,  Pierce Chem. Co.), 
1 mg/ml BSA (Fraction V, Sigma Chem. Co.), and 20 mM CaC12 contain- 
ing 0.5 nM 12sI-SGNL-BSA (or as indicated). The reaction tubes were agi- 
tated, and then incubated on a shaker at 4°C for 30 min (or as indicated). 
When lipids were added as inhibitors, they were evaporated from organic 
solvent  stock  solutions  under  a  stream  of  nitrogen  and  the  residue 
resuspended by bath sonication in 50 mM imidazole acetate, pH 7.4, con- 
raining 0.032 % Triton X-100 before appropriate dilution into binding buffer. 
For all inhibition studies, membranes were preincubated in binding buffer 
containing inhibitors for 30 rain at 40C before addition of radioligand and 
incubation for an additional 30 min. Subsequent to incubations, membrane- 
bound radioligand was separated from free ligand by filtration over glass 
fiber filters (Schleicher and Schuell, Inc.) using a Brandel Cell Harvester. 
The filters were pretreated with 1%  BSA in water to reduce background 
binding and were rinsed with 50 mM imidazole acetate, pH 7.4, before use. 
After filtration of the binding reactions, the filters were washed three times, 
"o3 ml each, with ice cold 50 mM imidazole acetate, pH 7.4. Radioactivity 
remaining  on  the  filter  was  measured  using  a  7-radiation  counter. 
Nonspecific binding was determined in the absence of CaCI2 or of mem- 
branes, as indicated. 
Lipid and Anionic Saccharide Inhibitors 
Sulfatide and globotetraosylceramide were obtained from Matreya,  Inc. 
(Chelfont, PA); cholesterol-3'-suifate,  galactosylceramide, and anionic sac- 
charides (except SGNL-oligosaccharide, see above) from Sigma Chem. 
Co.; phospholipids were obtained from Avanti Polar Lipids (Birmingham, 
AL) or from Sigma Chem. Co.; and individual purified bovine brain gan- 
gliosides were obtained either from Sigma Chem. Co. or E-Y Laboratories 
(San Mateo, CA). Synthetic 2,3 sialyl- and 2,6 sialyl Lewis x glycolipids 
(25)  were prepared by Dr. A. Hasegawa, Department of Applied Organic 
Chemistry, Gifu University, Japan, and were kindly provided by Dr. Brian 
Brandley,  Glycomed,  Inc.,  Alameda,  CA.  Sialylneolactotetraosylcera- 
mides were kindly provided by Paul James, Glycomed, Inc., Alameda, CA. 
Desulfated SGNL-lipid and its methyl ester were prepared by chemical 
modification of human canda equina SGNL-lipids by the method of Chou 
et al. (6). The purity and the concentrations of  the products were determined 
by quantitative TLC on silica gel HPTLC plates (E. Merck) using chloro- 
form/methanol/0.25 % KC1 as developing solvent, cupric sulfate/phosphoric 
acid char (61) for detection, and the parent SGNL-lipid as a standard for 
quantitation.  Each derivative appeared as a  single major species which 
migrated distinctly from the parent SGNL-lipid. The Rf values were as fol- 
lows: Parent lipid (predominantly IV3glucuronylneolactotetraosylceramide 
V3-sulfate), 0.35; desulfated SGNL-iipid (IV3glucuronylneolactotetraosyl  - 
ceramide), 0.39; and methyl esterified desulfated SGNL-lipid (IV3glucuro - 
nylneolactotetraosylceramide Vt-methyl ester), 0.59.  The identity of each 
lipid was confirmed by fast atom bombardment mass spectroscopy in the 
negative ion mode using a Finnigan MAT 900 spectrometer with triethyl- 
amine as matrix as kindly performed by Dr.  Hans Schweingruber, Gly- 
comed, Inc., Alameda, CA. Characteristic of glycosphingolipids (20), the 
Needham and Schnaar Receptor  for Sulfoglucuronyl (HNK-1) Glycolipids  399 parent SGNL-lipid produced a family of molecular ions representing hetero- 
geneity in the ceramide (lipid) moiety, with the major molecular ion (M-l) 
at 1593,  corresponding to a ceramide composed of Cls sphingosine and a 
C24:0 fatty acid amide as previously reported (6). The major molecular ion 
(M-l) generated by the desulfated species was  1513,  as expected,  and the 
methyl ester generated the same molecular species (M-CH3) as well as the 
molecular ion (M-l) at 1527  (24). 
Results 
SGNL-derivatized Radioligand Synthesis 
and Characterization 
A polyvalent SGNL-derivatized radioligand was prepared 
by covalently linking SGNL-oligosaccharides enzymaticaUy 
released from SGNL-lipids to a carrier protein, BSA. To this 
end, efficient methods for the purification of SGNL-glyco- 
lipids from peripheral nerve and the production of SGNL- 
oligosaccharides were developed. Dog sciatic endoneurium 
was chosen as the tissue source because of its relatively high 
abundance of SGNL-lipid (23).  The procedure for the puri- 
fication of SGNL-lipids was based upon the unexpected ob- 
servation that these highly polar lipids are differentially in- 
soluble in chloroform/methanol (1:1). When a chloroform/ 
methanol/water (4:8:3) lipid extract from dog sciatic endo- 
neurium was evaporated to d~ness and the residue reex- 
tracted with chloroform/methaaol  (1:1), '~98 % of the neutral 
lipids,  phospholipids,  and glycolipids (including ganglio- 
sides)  were  solubilized (30),  while '~70%  of the SGNL- 
lipids were recovered in the insoluble residue. The SGNL- 
lipids were further purified from lipid and polypeptide con- 
taminants by partitioning, DEAE-Sepharose chromatography, 
silicic acid chromatography, and reserve-phase chromatog- 
raphy to yield ~2.6 #mol of SGNL-lipids from I00 g (wet 
weight) of dog sciatic nerve endoneurium. Purified SGNL- 
lipids  consisted of two major  species,  resolved by  TLC, 
which correspond to the previously described (1,6) closely 
related  structures  IV3glucuronylneolactotetraosylceramide 
V3-sulfate (SGNL-lipid, 60%) and VI3glucuronylneolacto  - 
hexaosylceramide VIP-sulfate  (SGNLt-lipid,  40%)  (Fig. 
1). These species comigrated with known standards (kindly 
provided by Dr.  Robert Yu, Virginia Commonwealth Uni- 
versity, Richmond, VA) and were reactive with HNK-1 anti- 
body (data not shown). 
Treatment of the SGNL-lipids with leech ceramide glyca- 
nase (63) resulted in essentially complete conversion of the 
SGNL-lipids to the corresponding SGNL-oligosaccharides 
and ceramide. The oligosaccharides  were purified by reverse- 
phase chromatography and the purity of the products was 
confirmed by silica gel TLC developed in n-butanol/acetic 
acid/water (2:1:1).  The oligosaccharides were  detected as 
two species which migrated slower than the parent lipid spe- 
cies  (SGNL-lipid  Rf  =  0.49,  SGNL~-lipid  Rf  =  0.28, 
SGNL-oligosaccharide Rf =  0.11, SGNL~-oligosaccharide 
Rf =  0.05)  (data not shown). The SGNL-oligosaccharides 
were coupled to BSA by reductive amination, and the result- 
ing SGNL-BSA conjugate was purified by DEAE-HPLC and 
gel filtration chromatography. The SGNL-BSA was labeled 
to high specific activity with NalZ~I  for use as a radioligand 
(subsequent to labeling, 5 mg/mi of underivatized BSA was 
added to protect against radiation-induced damage). 
The derivatization ratio of the SGNL-BSA conjugate was 
determined by hydrolysis and saccharide analysis. Since the 
Figure I.. TLC analysis  of SGNL-lipid  purification from dog sciatic 
nerve endoneurium. Aliquots of lipid fractions derived from dog 
sciatic endoneurium  were applied to high performance TLC plates, 
developed in chioroform/methanol/0.25  % aqueous KCI (60:35:8), 
and visualized by CuSOdphosphodc acid char (61). Lipids were 
applied in amounts relative to the indicated starting wet weight of 
tissue: 1 nag (lane 1) and 2.5 mg (lane 2) equivalents  of total lipid 
extract; 2.5 rag (lane 3) and 50 mg (lane 5) equivalents  of the in- 
soluble lipid residue resulting from reextraction of total lipids with 
chloroform/methanol  (1:1); 2.5 nag equivalents  (lane 4 ) of  the lipids 
soluble in the chloroform/methanol (1:1) reextraction; and 50 mg 
equivalents (lane 6) of the purified SGNL-lipid fraction derived 
from further fractionation of the chloroform/methanol  (1:1) insolu- 
ble residue as detailed in Materials and Methods. 
glucuronic acid-galactose glycosidic linkage is resistant to 
hydrolysis, the conjugate was hydrolyzed after methyl es- 
terification and reduction of the glucuronic acid to glucose. 
Control hydrolysis of SGNL-lipids treated under identical 
conditions in the presence of underivatized BSA resulted 
in a galactose recovery which was 98% of theoretical. Sac- 
charide analysis of the hydrolyzed SGNL-BSA conjugate 
yielded ratios of galactose/N-acetylgucosamine (detected as 
glucosamine)/glucose of 2.4:1.56:1.2  (expected  monosac- 
charide  ratios  for  reduced  SGNL-oligosaccharides  (60% 
SGNL4/40%  SGNL)  =  2.4:1.4:1).  Based on the galactose 
recovery from the SGNL-BSA derivative, an average of 7.5 
SGNL-oligosaccharides were attached per BSA molecule. In 
addition, laser desorption mass spectroscopy was performed 
on the parent BSA and the SGNL-BSA conjugate. The parent 
BSA spectrum exhibited a peak of molecular ions centered 
at 68,400 mass units, while the SGNL-BSA derivative spec- 
trum exhibited a broader peak of molecular ions centered at 
75,000  mass units (data not shown). The difference, 6,600 
mass units, is equivalent to a derivatization ratio of 6 SGNL- 
oligosaccharides attached per BSA molecule. The covalent 
attachment of intact SGNL-oligosaccharides to BSA was 
confirmed by SDS-PAGE of radioiodinated SGNL-BSA and 
Western blot analysis with HNK-1 antibody, which requires 
the presence of  the sulfate on the SGNL-lipid for recognition 
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autoradiographic  analysis of 
nsI-SGNL-BSA.  Samples of 
nsI-SGNL-BSA (lane 1) and 
biotinylated molecular weight 
markers  (lane  2)  were  sub- 
jetted to electrophoresis in a 
10-20% SDS-polyacrylamide 
gel under reducing conditions 
and transferred to nitrocellu- 
lose for fluorographic (A) and 
immunoblot (B) analysis. The 
immunoblot  was  incubated 
with  HNK-1 antibody  and 
bound antibody was detected 
with  biotinylated  goat  anti- 
mouse IgM followed  by avidin/ 
biotinylated  horseradish perox- 
idase  complex.  Molecular 
masses of  the biotinylated mo- 
lecular mass markers (in kD), 
including  BSA  (66  kD)  are 
indicated. 
(24).  The  radioiodinated  conjugate  migrated  as  a  broad 
band, with a major radioiodinated product comigrating with 
the HNK-1 reactive band at an apparent molecular weight 
greater than that of  BSA (Fig. 2). No HNK-1 binding was de- 
tected against underivatized BSA (data not shown). The de- 
rivative is denoted (SGNL)TBSA, or simply SGNL-BSA, to 
be consistent with prior neoglycoconjugate  terminology (28). 
125I-SGNL-BSA Binding to Rat Peripheral Nerve 
Myelin Membranes 
Rat  PNS  myelin-enriched  membranes  were  isolated  by 
differential centrifugation and  discontinuous  sucrose gra- 
dient fractionation of rat sciatic nerve endoneurium. When 
~z*I-SGNL-BSA (0.7  nM)  was  incubated  with  increasing 
amounts of rat PNS myelin-enriched membranes and the 
bound ligand  separated  from the  free ~z~I-SGNL-BSA by 
filtration,  membrane-dependent  binding  was  readily  de- 
tected. Background binding was very low, '~,0.4%  of the to- 
tal added radioligand in the absence of added membranes. 
Initial experiments demonstrated that 10/zM SGNL-lipid re- 
duced the binding of the  tz*I-SGNL-BSA  to the same low 
background levels, as did omitting calcium from the binding 
buffer (see below). In subsequent experiments, specific bind- 
ing was defined as binding to membranes in the presence of 
20 mM CaC12 (total) less binding in the absence of calcium 
or in the absence of membranes (nonspecific). Binding in- 
creased proportionally with added membranes up to  1 /zg 
membrane protein (Fig.  3). 
In the presence of 0.5 nM ~sI-SGNL-BSA, binding to rat 
PNS membranes reached equilibrium within 30 min at 4°C 
(Fig. 4, filled circles). This incubation time was chosen for 
subsequent binding  studies.  Binding  as  a  function of the 
amount of membranes added indicated that the maximum 
amount of radioligand bound was well below that added (see 
Fig. 3). This was not unexpected, since the synthetic mul- 
tivalent ligand is inherently heterogeneous (see below). To 
determine if the ~25I-SGNL-BSA which remained unbound 
was  competent to  bind  to  fresh membranes,  membrane- 
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Figure 3.  Calcium-dependent binding of nsI-SGNL-BSA to rat 
PNS myelin as a function of membrane protein concentration. The 
indicated amounts of rat PNS myelin-enriched membranes (frac- 
tion S1A, see Materials and Methods) were incubated with 0.7 nM 
nsI-SGNL-BSA for 30 rain at 4"C in a total volume of 250/~1 
binding buffer in the presence or absence of 20 mM CaCI2, and 
membrane-bound ligand was separated from free ligand by filtra- 
tion. Nonspecific binding in the absence of calcium (zx) was sub- 
tracted from total binding in the presence of calcium (o) to yield 
specific binding (o). Values are the mean 5: SD for triplicate (total) 
or duplicate (nonspecific) determinations (SD values which fall 
within the symbols are not shown). 
bound radioligand was separated from flee radioligand by 
filtration and a second aliquot of membranes was added to 
the free mI-SGNL-BSA in the filtrate. Radioligand bound 
after a  second incubation of 30 min was then determined 
(Fig.  4,  open  circles).  The  sum  of the  125I-SGNL-BSA 
bound after the first and second incubations, expressed as a 
percent of the input ligand, was constant and indicated that 
,,o6% of the m~I-SGNL-BSA was competent to bind to rat 
PNS myelin-enriched membranes (Fig. 4, triangles). Inclu- 
sion  of the  protease  inhibitors  phenylmethylsulfonylfluo- 
ride, leupeptin, antipain, benzamidine, aprotinin, chymosta- 
tin,  and pepstatin in the binding buffer did not affect the 
kinetics of binding nor the maximal amount of radioligand 
bound (data not shown). To evaluate the molecular heteroge- 
neity of the bound and the free nsI-SGNL-BSA, membrane- 
bound radioligand was separated from free radioligand by 
centrifugation, and the two pools were analyzed by Western 
blot HNKq immunostaining and autoradiography subsequent 
to SDS-PAGE.  Both pools were HNK-1 reactive: the free 
~25I-SGNL-BSA was  indistinguishable  from the  total  ~zsI- 
SGNL-BSA, while the bound nsI-SGNL-BSA exhibited en- 
richment for higher molecular weight HNK-1 reactive iodi- 
nated species. (No HNK-1 staining was detected against rat 
PNS membranes alone, data not shown.) 
Binding isotherms were performed with increasing con- 
centrations of ~25I-SGNL-BSA incubated for 30 min  with 
0.25  #g membrane protein.  As  the  concentration of t~I- 
SGNL-BSA was increased, nonspecific background binding 
of radioligand  (binding to filters in the absence of mem- 
branes but presence of calcium [Fig. 5 A, triangles], or in 
the  presence of membranes  but  absence of calcium  [not 
shown]) increased in a  nonsaturable, linear manner as ex- 
pected. Specific binding of nsI-SGNL-BSA to rat PNS my- 
elin-em'iched membranes was saturable and exhibited high 
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Figure 4. Kinetics  of t25I-SGNL-BSA binding to rat PNS myelin 
and competency of the unbound radioligand  to bind fresh mem- 
branes.  Rat PNS myelin-enriched membranes (fraction S1A) were 
incubated with 0.5 nM ~2sI-SGNL-BSA  under standard conditions 
except that the volume of  each binding reaction was increased 8-fold 
to 2 ml and the total membrane protein added to each reaction was 
60 #g. After the indicated  times at 4°C, the reaction was filtered 
through glass fiber filters (Whatman GFC) and the filtrate collected 
for further use (see below).  The filters were then rapidly washed, 
collected, and radioactivity quantitated  to determine binding ki- 
netics (e). To 225 #1 of the binding assay filtrate collected at each 
indicated time was added fresh myelin membranes (7.5 #g in 25 #1 
0.29 M sucrose).  After an additional  30 min at 4°C, ligand bound 
to membranes after this second incubation was separated  from free 
ligand by filtration and quantitated  as in the standard assay to deter- 
mine the percent of unbound ligand at each time which was compe- 
tent to bind to fresh membranes (o). Nonspeeific  binding (in the 
absence of CaC12, < 0.8% of added ligand) was determined in par- 
allel incubations  and was subtracted  from total binding.  Data are 
presented as percent of added ligand specifically bound during the 
initial incubation (e), after the second incubation with fresh mem- 
branes (o) and the sum of  these two incubations  (zx). Values are the 
mean  -t-  SD for triplicate  determinations  (SD values  which fall 
within  the symbols are not shown). 
affinity (Fig.  5 A,  filled circles).  Nonlinear fit of the data 
using a single site model resulted in a Ko of 320 pM and a 
B,~  of 370 pmol/mg protein  (Fig.  5 A,  solid line).  How- 
ever, unexpectedly high binding at the lower end of the titra- 
tion curve was consistently observed, and Scatchard trans- 
formation (49) of the binding isotherm data was curvelinear 
(Fig. 5 B), consistent with the presence of a low abundance, 
higher-affinity subpopulation of binding sites when fit to a 
two site model (high-affinity class KD =  17 pM, I3.= =  38 
pmol/mg membrane protein; lower-affinity class KD =  460 
pM,  Bm~  =  330 pmol/mg membrane protein).  For deter- 
mining binding constants, the unbound (free) ligand concen- 
tration was calculated based on the proportion of total t25I- 
SGNL-BSA competent  to  bind  rat  PNS  myelin-enriched 
membranes  (see Fig.  4),  which was experimentally  deter- 
mined in a parallel binding assay containing 0.5 nM ligand 
and an excess (10 #g) of membrane protein. 
Experiments  to  test  whether  SGNL-specific  antibodies 
(23)  would  block  ~25I-SGNL-BSA binding  to  membranes 
were inconclusive,  since control immunoglobulins  (mouse 
IgM and IgG) interfered  with the binding assay as did the 
corresponding monoclonals HNK-1  (IgM) and F7F7  (IgG) 
(data not shown). The basis of the interference was not deter- 
mined. 
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Figure 5. Saturation  isotherms for 12sI-SGNL-BSA binding  to rat 
PNS myelin.  (A) Rat PNS myelin-enriched membranes (fraction 
S1A, 0.25 #g protein)  were incubated  with increasing  concentra- 
tions of 125I-SGNL-BSA  in 250 #l binding  buffer  containing 20 
mM CaC12. After 30 rain at 4°C,  membrane-bound ligand  was 
separated  from free ligand  by filtration  (o, total ligand  bound). 
Nonspecific  ligand bound (zx) was determined in parallel  incuba- 
tions in the absence of membranes, and was subtracted  from total 
bound to calculate  specific bound (e). Values are the mean +  SD 
for quadruplicate  (total binding) or triplicate  (nonspecific binding) 
determinations  (SD values  that fall  within  the  symbols are not 
shown).  The abscissa  is the concentration of free ~25I-SGNL-BSA 
competent to bind PNS myelin membranes (see tex0. Free ligand 
was calculated as the amount of  radioligand added times the propor- 
tion of ligand  (5.3%)  competent to bind (to an excess  of mem- 
branes, 10 #g) less the specifically bound ligand. The solid line was 
generated by a nonlinear fit of  the specific binding data using a sin- 
gle site binding model and yielded the indicated  apparent dissocia- 
tion constant (Ko) and total receptor density (B~). (B) Scatchard 
transformation  of specific ~25I-SGNL-BSA  binding to rat PNS my- 
elin.  Data for the specific binding isotherm (Fig. 5 A) was trans- 
formed by the method of Scatchard (49) (e). The dashed fines were 
fit to the curve using a two-site model and yielded the indicated ap- 
parent dissociation  constant (Ko) and total receptor concentration 
(Bmax)  values. 
Divalent Cation, Ionic Strength, and pH Effects on 
125I-SGNL-BSA Binding 
Ligand binding was studied as a function of divalent cation 
concentration,  using  a  variety  of divalent  cations  over  a 
broad concentration range (Table I). Divalent cations were 
required for binding and calcium supported higher specific 
binding  than  other  divalent  cations  tested.  Half-maximal 
binding of ~2q-SGNL-BSA to rat PNS myelin occurred at 
5 mM Ca  +2, with maximal binding at 10 mM Ca  +: (Fig. 6). 
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Binding to PNS Myelin 
Divalent ion  Concentration  t2~I-SGNL-BSA  Bound* 
mM  % of control 
None  0.1  +  0.3 
SrCI2  2.5  7.9  5-  3.9 
5  25  +  3.3 
10  51  +  6.9 
20  88 +  9.4 
30  62  +  3.2 
40  45 +  3.9 
MgC12  2.5  11  +  9.8 
10  21  +  6.8 
20  38 +  2.8 
30  35 +  3.2 
BaCI2  2.5  7.4  +  1.0 
10  27  +  3.0 
20  34 + 4.5 
30  21  +  1.9 
CoCI2  2.5  9.4  + 4.5 
10  27 +  3.0 
20  33 +  2.9 
30  20 +  2.7 
MnCI2  2.5  4.4  +  2.2 
10  10 +  3.8 
20  26 +  10 
30  35 +  4.4 
40  52  +  2.7 
Rat PNS myelin-enriched  membranes (fraction S 1  A, 0.25 #g protein) were in- 
cubated  with 0.5  nM  t2~I-SGNL-BSA for 30 min at 40C  in 250 #l  binding 
buffer containing the indicated divalent cation  salts in the absence of CaCl2. 
Values are the mean  ±  SD for triplicate determinations. 
* Specific binding  was determined  at each  salt concentration  by subtracting 
nonspecific binding in the absence of membranes from total binding in the com- 
plete reaction.  Data are expressed as the percent of control specific binding in 
the presence of 20 mM CaCI2 (specific binding for three experiments  ranged 
from 2.5  to 5.8  fmol per reaction). 
Among other divalent cations tested,  Sr  +2 supported maxi- 
mal binding that was 88%  of that in the presence of Ca  +2, 
while other divalent cations  (Ma  +2, Ba  +2, Co  +2, and Mn  +2) 
supported much less binding (Table I). While divalent cat- 
ions were required for binding, they could be omitted from 
the filter wash buffer without reducing specific binding, sug- 
gesting that little dissociation occurred during the rapid (~1 
min)  wash.  Subsequent  experiments were performed with 
divalent cation omitted from the filter wash. 
Increasing ionic  strength  decreased specific binding,  as 
can be  seen  with  higher  calcium  chloride  concentrations 
(Fig.  6).  Similarly, addition  of MgC12, MgSO+,  NaCl,  or 
KCl reduced radioligand binding to half-maximal levels at 
concentrations ranging from ~25 to 50 mM. No significant 
variation  in  binding  was  detected  over  the  pH  range  of 
6.0-8.0 (in 50 mM imidazole acetate buffer). 
SubceUular and Nervous System Distribution of 
1zsI-SGNL-BSA Binding 
Peripheral  nerve  membrane  fractions  were  isolated  by 
differential  centrifugation  and  discontinuous  sucrose  gra- 
dient centrifugation. Sciatic nerve endoneurium homogenate 
was centrifuged  (low speed) to yield a  crude supernatant 
fraction (S1),  a portion of which was centrifuged at higher 
speed to yield a mixed membrane (P2) fraction. Most of the 
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Figure 6. Binding of t25I-SGNL-BSA  to rat PNS myelin as a func- 
tion  of calcium  concentration.  Rat  PNS  myelin-enriched  mem- 
branes (fraction S1A, 0.25 #g protein) were incubated with 0.5 nM 
125I-SGNL-BSA for 30 rain  at 4°C in a total volume of 250 #1 
binding buffer containing  the indicated concentrations  of CaCI2, 
and the membrane-bound ligand was separated from the free ligand 
by filtration (o, total binding). Nonspecific binding (a) was deter- 
mined in parallel incubations in the absence of membranes, and was 
subtracted  from total binding  to calculate  specific binding  (e). 
Values are the mean + SD for triplicate (total binding) or duplicate 
(nonspecific binding) determinations (SD values that fall within the 
symbols are not shown). 
crude S1  was subjected to discontinuous  sucrose gradient 
centrifugation  to yield myelin-enriched membranes (S1A) 
and denser mixed membranes (S1B).  A portion of S1A was 
further subjected to osmotic shock and a second discontinu- 
ous sucrose gradient,  to generate myelin fraction $2 (42). 
t2q-SGNL-BSA binding  was  clearly enriched  in  fractions 
containing PNS myelin (Fig.  7 A,  Table ID, while denser 
PNS membranes (S1B) had little binding activity. 
Membrane fractions were also prepared from the CNS for 
comparison to PNS myelin binding of 125I-SGNL-BSA.  A 
mixed membrane P2 fraction prepared from whole rat brain 
by differential centrifugation (11) and consisting of myelin 
membranes, synaptosomes, and mitochondria, had very low 
binding activity (Fig. 7 B), as did brain membranes further 
fractionated by discontinuous sucrose density centrifugation 
to yield crude myelin (P2A) and crude synaptosomal (P2B) 
fractions  (19).  Under  identical  conditions,  PNS  myelin 
membranes bound  20-40-fold  more  125I-SGNL-BSA  than 
did any of the CNS membrane fractions. 
Among adult CNS brain regions, SGNL-lipids are found 
exclusively in the cerebellum (43). Therefore, cerebellar P2 
membranes were prepared and  tested  for  125I-SGNL-BSA 
binding activity. Like whole brain membrane fractions, cere- 
bellar membranes failed to bind significant ligand (Fig. 7 B). 
Carbohydrate Specificity  of lz'I-SGNL-BSA Binding 
Various compounds including SGNL-lipids and other sulfo- 
lipids,  gangliosides,  neutral  glycosphingolipids,  phospho- 
lipids,  mono-  and  oligosaccharides,  glycosaminoglycans, 
and other anionic polysaccharides, were tested for their abil- 
ity to inhibit  ~25I-SGNL-BSA binding to rat PNS  myelin- 
enriched membranes. 
SGNL-lipids isolated from two sources,  human and bo- 
vine cauda equina, were the most potent of the lipids tested 
Needham and Schnaar Receptor for Sulfoglucuronyl (HNK-1) Glycolipids  403 10  A 
8 
////  , 
2  -- 
7 
o  O-  '  // 
rn 
0.0  0.5  1.0 
"O 
t- 
O 
o,10 
..J 
O 
8 
O 
¢J 
CL 
o~  6 
I 
10.( 
i  i  i  i 
B 
2  i 
0.0  0.5  1.0 
4 
0.0  2.5  5.0  7.5  10.0 
Protein  (/zg) 
Figure 7. Binding of ~I-SGNL-BSA to rat PNS endoneurium and 
brain subcellular fractions. (,4) Rat peripheral nerve endoneurium 
homogenate  was  fractionated by  differential centrifugation (A, 
crude homogenate, S1; v, mixed membranes, P2) and discontinu- 
ous sucrose gradient centrifugation of S1 (e, myelin-enriched, SIA; 
*,  dense-membranes, S1B), or of osmotically shocked S1A (a, 
$2) as described in Materials and Methods. (B) Whole rat brain 
homogenate  was  fractionated by  differential centrifugation  (XT, 
mixed membranes,  P2) and discontinuous sucrose gradient cen- 
tdfugation (o,  myelin-enriched, P2A;  <>,  synaptosomes, P2B), 
and rat cerebellum homogenate was fractionated  by differential  cen- 
trifugation (ra, mixed membranes, cerebellar, P2) as described in 
Materials and Methods.  Specific binding of 0.5  nM  125I-SGNL- 
BSA to aliquots of PNS or CNS fractions containing the indicated 
amounts of protein was determined as described in Fig. 3. Values 
are the mean -I- SD for triplicate determinations (SD values which 
fall within the symbols are not shown). 
as inhibitors (Fig. 8, Table HI), with IC50 values in the sub- 
micromolar range. Gangliosides (sialic acid-bearing anionic 
glycosphingolipids) exhibited a  range of inhibitory poten- 
cies, all less potent than SGNL-Iipid. The gangliosides GM~ 
and Grab failed to inhibit half-maximally even when present 
at 100/xM, while Grtb and Got, inhibited binding with aver- 
age ICs0's of >~ 33  #M.  Unlike inhibition by SGNL-lipids, 
there was significant variability in ganglioside inhibition be- 
tween  experiments  (Table  HI).  Gangliosides with  neutral 
saccharide core structures of the neolacto series (the same 
neutral  core  as  SGNL-lipids) were  also  tested  as  inhibi- 
tors: sialylneolactotetraosylceramide  (41% sialyl[2-3], 59% 
sialyl[2-6]) inhibited with an IC~o of 40/~M, while the sial- 
ylated  fucosylated  neolactotetraosylceramides  2,3  sialyl 
Lewis x- and 2,6 sialyl Lewis x glycolipids failed to inhibit 
significantly at  10/zM  (the  highest concentration  tested). 
Table II.  t251-SGNL-BSA  Binding  Activity to Peripheral 
Nerve Membrane Fractions 
Total  Binding  Binding  Binding 
Fraction  protein  activity  recovery  enrichment 
mg  pmol/mg  protein  %  -fold 
S1  42.8  3.8  -t- 1.0  100  1.0 
P2  23.8  5.8  -t- 1.0  85  1.5 
SIA  17.7  10.7  -I- 1.2  116  2.8 
S1B  0.8  3.0  +  1.7  1.5  0.8 
$2  6.8  11.5  +  2.8  48  3.0 
Specific binding of nsI-SGNL-BSA  to peripheral nerve homogenate (SI), 
crude membranes (P2), and fractions  prepared  by successive  discontinuous  su- 
cruse gradient  centrifugation  (S1A, SIB, and $2) as detailed  in Materials  and 
Methods was determined  as described in the legend to Fig. 3. The specific 
binding activity is reported as the mean +  SD for three determinations  per- 
formed in triplicate in the linear protein range (0.1, 0.25, and 0.5 /*g mem- 
brane protein, see Fig. 7). 
The sulfated lipids sulfatide and cholesterol sulfate inhibited 
with moderate potency (ICs0's >/8/zM). 
Neutral glycosphingolipids and most phospholipids failed 
to inhibit half-maximally even at 100 #M. Phosphatidylglyc- 
erol did inhibit, although its inhibition was dependent upon 
the fatty acid content. Synthetic phosphatidylglycerol  having 
fully saturated fatty acids was noninhibitory (at  100 #M), 
while phosphatidylglycerol having saturated fatty acids in- 
hibited with an ICs0 of 8.3/zM. The significance of this ob- 
servation is unknown. 
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Figure 8.  Inhibition of ~2sI-SGNL-BSA binding to rat PNS myelin 
by lipids. Rat PNS myelin-enriched membranes (fraction S1A, 7.5 
/~g protein) were preincubated with the indicated concentrations of 
inhibitor for 30 rain at 4°C in 225/zl binding buffer in the presence 
or absence of CaCl2,  and then  125I-SGNL-BSA was added to a 
final concentration of 0.5 nM (250 td total binding buffer volume). 
After further  incubation for  30  rnin  at  4°C,  membrane-bound 
ligand was separated from free ligand by filtration. At each inhibi- 
tor  concentration,  the  amount  of  ~25I-SGNL-BSA specifically 
bound (defined as binding to membranes in the presence of 20 mM 
CaCI2 minus nonspecific binding to membranes in the absence of 
CaCI2) was determined and is expressed as the percent of specific 
control binding in the absence of inhibitor (control binding was 
5.8  ±  0.1 fmol). Values are the mean +  SD for triplicate determi- 
nations (SD values which fall within the symbols are not shown). 
The lipids tested were e, SGNL-lipid (human);  A, sulfatide; o, 
cholesterol sulfate,  D,  G~b;  and  ~,  GD~. Non-inhibitory lipids 
(not shown) are listed in Table HI. 
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Myelin by Lipids 
Lipids (n)  ICs0 (range) 
t,M 
SGNL-lipid,  bovine (5)  0.99  (0.55-1.2) 
SGNL-lipid, human (7)  0.48 (0.3-0.6) 
Desulfated SGNLdipid, human (2)  1.5 (1-2) 
Methyl esterified, desulfated 
SGNL-Iipid, human (1)  >25 
sulfatide (4)  8.2 (4-12) 
cholesterol sulfate (2)  10 (6.2-14) 
sialylneolactotetraosylceramide  (1)  40 
2,3 sialyl Lewis x glycolipid (1)  >10 
2,6 sialyl Lewis x glycolipid (1)  >10 
G'rlb (4)  33 (6-64) 
GDIa (2)  58 (15->100) 
Gl)lb (2)  >100 
GMI (1)  >100 
globotetraosylceramide  (1)  >100 
galactosylceramide (1)  >100 
phosphatidylglycerol (2)*  >100 
phosphatidylinositol (1)  >100 
phosphatidylinositolbisphosphate (1)  >100 
phosphatidylserine (1)  >100 
phosphatidic acid (1)  >100 
phosphatidylcholine (1)  >100 
phosphatidylethanolamine (1)  >100 
Inhibition studies were performed as described in the legend to Fig.  8.  The 
mean and range of concentrations of each inhibitor resulting in 50% inhibition 
(ICso) of specific  t2~I-SGNL-BSA binding in the absence of inhibitor was de- 
termined graphically from the indicated number (n) of independent binding ex- 
periments performed at  four to  seven concentrations of each  inhibitor  in 
triplicate.  Control binding was comparable to that shown in Fig. 3. 
* Results are for phosphatidylglycerol having unsaturated fatty acid chains 
(Cts:0). The same phospholipid having a mixture of natural fatty acids had an 
ICs0 of 8.3 t~M. Other phospholipids tested had natural fatty acids. 
The molecular determinants responsible for inhibition of 
~2q-SGNL-BSA  binding  to  rat  PNS  myelin  were  inves- 
tigated using chemically modified SGNL-lipid. Treatment of 
the SGNL-lipid with methanolic HCI resulted in concomi- 
tant removal of the 3-O-sulfate from the nonreducing termi- 
nal glucuronic acid and methyl esterification of the carbox- 
ylic acid  at the  6-position of the  glucuronic acid  (6).  A 
portion of the methyl esterified glycolipid was converted to 
the  desulfated  parent  molecule  by  alkali  treatment  (6). 
Desulfated SGNL-lipid remained one third as potent as the 
parent SGNL-lipid in inhibiting ~2~I-SGNL-BSA binding to 
rat  PNS  myelin.  In  contrast,  methyl esterification of the 
desulfated SGNL-lipid blocked its ability to inhibit (Fig. 9, 
Table HI). 
Anionic monosaccharides (glucuronic acid and N-acetyl- 
neuraminic acid),  SGNL oligosaccharides (liberated from 
dog SGNL-lipids by ceramide glycanase), and 3'-sialyUac- 
tose did not inhibit t2sI-SGNL-BSA binding to rat PNS my- 
elin membranes at the highest concentrations tested (5 mM). 
Glycosaminoglycans  (polysaccharides containing uronic acids 
and/or sulfated saccharide residues), and dextran sulfate (a 
synthetic sulfated polysaccharide) inhibited binding without 
specificity when added in the range of 0.1 #g/ml. Colominic 
acid, an anionic polymer of sialic acids, was a weaker inhibi- 
tor, with an IC50 of 100/xg/ml. 
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Figure 9. Inhibition of t25I-SGNL-BSA  binding to rat PNS myelin 
by  SGNL-lipid  derivatives. Desulfated  and  methyl  estedfied 
SGNL-lipid (n)  and desulfated SGNL-lipid (o)  were prepared 
from  human  SGNL-lipid  (e)  as  described  in  Materials  and 
Methods. Inhibition studies were performed as described in Fig. 8. 
125I-SGNL-BSA specifically bound at each lipid concentration is 
expressed as the percent of specific control binding in the absence 
of inhibitor (control binding was 5.2 ±  0.3 fmol). Values are the 
mean  ±  SD for triplicate determinations (SD values which fall 
within the symbols are not shown). 
Protease Sensitivity oft2~I-SGNL-BSA Binding Activity 
Preincubation of 0.25 t~g of PNS myelin membrane protein 
with 0.01-0.5/xg trypsin and subsequent inactivation of the 
trypsin through the addition of soybean trypsin inhibitor re- 
suited  in  a  concentration  dependent  attenuation  of  ~25I- 
SGNL-BSA binding to <50 % of control. Increasing trypsin 
to 5/~g during the preincubation (with subsequent addition 
of trypsin inhibitor) did not result in a further decrease in 
radioligand bound, which remained at 29-51% of that bound 
to control membranes in various experiments. Pretreatment 
of membranes with trypsin inhibitor alone or with trypsin in 
the  presence of trypsin  inhibitor  had  little  effect on the 
amount of radioligand bound (data not shown). Pronase pre- 
treatment of myelin membranes (12.5/~g of membrane pro- 
tein pretreated with 0.01-5  Ixg pronase, and the membranes 
recovered by centrifugation in the presence of excess BSA) 
also resulted in a concentration dependent, but incomplete, 
reduction of ~25I-SGNL-BSA binding to 42 % of that bound 
to control membranes. Binding activity on myelin membranes 
was heat stable, in that boiling did not reduce the amount of 
radioligand bound. 
Discussion 
The formation and maintenance of the multilameUar myelin 
sheath of axons depend upon coordinate cell surface recog- 
nition and interaction, both between the apposed membranes 
of the myelin-forming cell and the neuron, and between the 
scrolled myelin membranes themselves. Several coexisting 
families of adhesion molecules involving direct protein to 
protein interaction have been implicated in these cell-sur- 
face interactions of the myelin-forming cell of the PNS, the 
Schwann  cell.  We  have focused on  the  potential  role of 
carbohydrates as determinants recognized by Schwann cell 
surface receptors, and have proposed that the unusual snl- 
foglucuronylneolacto-glycolipids  may function as recognition 
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sistent with this role, our previous studies demonstrated that 
SGNL-lipids specifically support Schwann cell adhesion. 
Our strategy to identify the hypothetical SGNL receptor 
on PNS myelin depended on the synthesis of a complemen- 
tary high affinity radioligand. Since carbohydrate recogni- 
tion often requires appropriate juxtaposition of multiple car- 
bohydrate  binding  determinants  (32),  we  constructed  a 
multivalent SGNL-derivatized ligand that could be readily 
radiolabeled. This task was facilitated by a relatively rapid 
purification technique for SGNL-lipids and by the use of the 
enzyme ceramide glycanase to release SGNL-oligosaccha- 
rides, which could be linked to a BSA carrier to generate a 
multivalent radioiodinated ligand, 125I-SGNL-BSA. Carbo- 
hydrate analysis confirmed the  multivalent nature  of the 
ligand, and immunoblot analysis subsequent to SDS-PAGE 
indicated that HNK-1 reactive epitopes were covalently at- 
tached to the BSA. Since HNK-1 reactivity requires the sul- 
fate  on  the  glucuronyl  moiety  and  is  abrogated  if the 
glucuronyl carboxyl moiety is removed (24),  the immuno- 
blot data demonstrated that (SGNL)TBSA carried intact sul- 
foglucuronyl epitopes. 
~2q-SGNL-BSA was  a  successful ligand for identifying 
SGNL-directed binding activity on PNS membranes. The 
characteristics of this high-affinity  and saturable binding ac- 
tivity were remarkable for a number of reasons. Within the 
PNS,  binding was enriched on myelin rather than denser 
membranes. This suggests that the binding activity is a prod- 
uct of Schwann cells, and may be involved in their myelinat- 
ing  function.  Our  previous  finding  that  intact  primary 
Schwann cells bind to SGNL-lipids resolved by TLC chro- 
matograms (38, 39) is consistent with a cell adhesion func- 
tion  for  SGNL  lipids  and  complementary  Schwann  cell 
receptors. The absence of ~z~I-SGNL-BSA binding on CNS 
membranes, and especially on CNS myelin, is also of note. 
A CNS myelin ganglioside binding activity which appears to 
be a product of oligodendrocytes, but which is absent from 
PNS myelin, may be a complementary CNS system for axon 
recognition (58, 59). 
The possibility that the SGNL-binding site is a membrane 
protein is supported by the finding that preincubation of PNS 
myelin membranes with trypsin or pronase partially abro- 
gates  the  subsequent binding of t25I-SGNL-BSA to  these 
membranes. The observation that binding of ~25I-SGNL-BSA 
was calcium-dependent may relate this activity to a family of 
vertebrate calcium-dependent carbohydrate binding proteins 
(15) including the selectins (54) and the glycoprotein recep- 
tors on hepatocytes and macrophages. The calcium require- 
ment clearly distinguishes this activity from the broadly dis- 
tributed galactose binding proteins which can be found in the 
PNS (21) as well as from the CNS myelin ganglioside binding 
activity mentioned above  (59). 
A consistent observation during these studies was that only 
a  small portion of added radioligand (*6%)  specifically 
bound to PNS myelin membranes, even when membranes 
were added in excess.  The observations that recovered, un- 
bound  ~2q-SGNL-BSA did not bind to fresh membranes, 
yet remained as macromolecular, HNK-1 reactive material, 
suggests that the ligand itself is structurally heterogeneous. 
This is not surprising, since random glycosylation  of  an aver- 
age of 7.5 of  the 60 lysines on BSA would be expected to gen- 
erate a statistical variation in glycosylation  number and even 
more variation in the relative spatial arrangement of oligo- 
saccharides on the carrier. Studies in other carbohydrate rec- 
ognition systems demonstrate that precise spatial relation- 
ships can be critical to high-affinity binding of multivalent 
glycoconjugates (32, 46). Our data suggest that the valence 
and/or the spatial arrangement of the oligosaccharides on a 
subpopulation (•6%)  of the ~25I-SGNL-BSA molecules is 
appropriate for high-affinity ligand binding. SGNL-lipids in 
natural membranes are most likely laterally mobile and may 
adopt the required valence and  juxtaposition. Consistent with 
this model, monovalent SGNL-oligosaccharides failed to in- 
hibit binding of  the multivalent  derivative to PNS myelin even 
when present at concentrations as high as 5 mM. In contrast, 
SGNL-lipids, added as detergent mixed micelles, specifically 
inhibited binding with an IC50 <  1 #M. Such marked differ- 
ences between glycolipids and their monovalent oligosaccha- 
ride constituents have also been reported for other carbohy- 
drate recognition systems (32,  58). 
In performing kinetic analyses of ~25I-SGNL-BSA bind- 
ing, the maximum percentage of ligand competent to bind 
was experimentally determined to allow accurate calculation 
of the unbound, competent ligand concentration. Based on 
this analysis, the affinity is very high, with a Ko of 320 pM 
when fit to one site.  However,  Scatchard transformation of 
the binding isotherm was curvilinear, consistent with multi- 
ple classes of  binding sites or ligands. The presence of  multi- 
ple ligands with distinct binding affinities would be most 
consistent  with  our  hypothesis  that  valence  and  spatial 
configuration of the SGNL-oligosaccharides on the carder 
protein influence binding, although multiple classes of bind- 
ing sites are also possible. 
The higher binding affinity of the competent binding frac- 
tion of SGNL-BSA (KD  =  320 pM) compared to SGNL- 
lipid (K  I ,,ol #M) may reflect differences in effective valence 
and/or presentation of the SGNL-oligosaccharides. Lipid in- 
hibitors were added in the presence of 0.032 % Triton X-100, 
a concentration sufficient  to form micelles in which the lipids 
distribute, most likely at low valence.  The orientation of the 
oligosaccharide chain may also be effected by glycolipid in- 
sertion in a detergent miceUe. Nevertheless, the carbohydrate- 
specificity of 12q-SGNL-BSA binding was notable, in that 
among many anionic and neutral  glycosphingolipids and 
phospholipids tested under identical conditions, SGNL-lipid 
itself was the most potent inhibitor of 125I-SGNL-BSA bind- 
ing to PNS myelin (Table III). Surprisingly, the sulfate group 
on the glucuronic acid moiety was not required for SGNL- 
lipid recognition, although sulfate removal reduced SGNL- 
lipid inhibitory potency to one third that of the parent mole- 
cule. In contrast, esterification of the glucuronic acid (on 
desulfated SGNL-lipid) essentially eliminated its inhibitory 
activity (see Fig. 9).  This is of interest, since nonsulfated 
forms of the SGNL-lipid are broadly distributed phyloge- 
netically (14) and may be more ancient in evolution. Some 
role for the sulfate in binding was indicated by the observa- 
tion that sulfatide (sulfate-3-galactosylceramide) inhibited 
125I-SGNL-BSA binding (with an order of magnitude lower 
potency than SGNL-lipid) while its parent molecule, galac- 
tosylceramide, failed to inhibit. Gangliosides, anionic glyco- 
sphingo-lipids containing carboxylic acid groups on sialic 
acid moieties rather than on glucuronic acid, were either 
noninhibitory or  were  much  less  potent  inhibitors  than 
SGNL-lipid or desulfated SGNL-lipid (Table III). Of par- 
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has the same neutral saccharide core as SGNL-lipid but with 
a  sialic  acid  rather  than  a  glucuronic  acid  linked  to  the 
3-position of the outermost galactose, exhibited an inhibitory 
potency that was <4 % that of the desulfated SGNL-lipid. Al- 
though the precise carbohydrate  specificity has not been de- 
fined, these data suggest that the SGNL-binding site revealed 
by  J25I-SGNL-BSA  binding  has  specificity  for glucuronic 
acid moieties, and is enhanced by the sulfate group.  This 
hypothesis is strengthened  by the finding that glycosamino- 
glycans or polysulfated dextran inhibited the binding of 125I- 
SGNL-BSA to PNS myelin much more potently than did colo- 
minic acid,  an anionic polymer of sialic acid.  These data 
indicate that charge density,  per se,  is not responsible for 
SGNL-BSA binding, although all highly multivalent sulfated 
or uronic acid-containing polymers tested were moderately 
potent inhibitors. For example, hyaluronic  acid (glucuronic 
acid-N-acetylglucosamine  copolymer) inhibited  t25I-SGNL- 
BSA binding at 0.1/~g/ml, or 260 nM in glucuronic acid resi- 
dues. This can be compared to SGNL-BSA, which inhibited 
at 2.4 nM in glucuronic acid residues. Nevertheless, proteo- 
glycan inhibition may indicate a meaningful specificity for 
this PNS-binding activity. 
In some species, quantitatively  minor isoforms of certain 
glycoproteins (including the PNS myelin adhesive glycopro- 
teins MAG and P0) bind to HNK-1  antibodies,  raising the 
possibility that the SGNL-binding activity we have identified 
is directed towards these  glycoproteins  rather  than  glyco- 
lipids.  This is particularly  unlikely in the rat PNS,  where 
MAG  and  P0 do not carry  HNK-1  reactive epitopes  (41). 
Therefore, it is likely that the binding activity that we have 
characterized  is  functionally  specific  for interaction  with 
SGNL glycosphingolipids. More direct tests of glycoprotein 
vs.  glycolipid  binding  specificity  experiments  are  not yet 
meaningful,  since  the  SGNL  structure  has  yet  to  be 
identified on any of the HNK-l-reactive  glycoproteins. 
Some well defined proteins have been previously reported 
to bind to SGNL-lipids,  including laminin (36),  P30 (37), 
serum amyloid P component (34),  and L- and P-selectins 
(40). Of these, laminin is a component of Schwann cell base- 
ment membranes (10), and P30 has been found in Schwann 
cells and the peripheral nerve (13)  while the selectins and 
amyloid P have not been reported in the peripheral myelin. 
The binding characteristics and tissue distribution differenti- 
ate these proteins from the novel binding activity detected in 
PNS myelin in this study.  Neither laminin nor P30 exhibits 
calcium dependence  for binding to SGNL-lipids.  Further- 
more,  laminin  has  greater  avidity  for  sulfatide  than  for 
SGNL-lipids  and requires the  sulfate on SGNL-lipids  for 
avid binding (36).  While the carbohydrate  structural  spec- 
ificity of P30 has not been as fully established, it was isolated 
from rat cerebellar membranes (37) where we were unable 
to detect  t25I-SGNL-BSA  binding.  L- and  P-selectins bind 
avidly to sialyl Lewis x glycolipids in a calcium-dependent 
manner, while their binding to SGNL-lipids is calcium-inde- 
pendent (40),  both properties which are not shared  by the 
PNS myelin ~25I-SGNL-BSA binding site. 
In  conclusion,  we  have  identified  and  characterized  a 
novel, calcium-dependent, tissue- and carbohydrate-specific 
SGNL-oligosaccharide-binding activity on rat PNS myelin. 
The prior observations (38, 39) that SGNL-lipids, which are 
present both in the axolemma and (in smaller amounts) in 
myelin and other Schwann cell membranes, support specific 
adhesion of rat Schwann cells suggest that the PNS myelin 
SGNL-lipid binding activity  may be involved in Schwann 
cell-axon or myelin lamellae-lamellae  membrane interac- 
tions necessary for myelination or myelin maintenance. 
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